{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:01:03Z","timestamp":1791313263720,"version":"4.3.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003196 and 82270198"],"award-info":[{"award-number":["82003196 and 82270198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of hematological malignancies with poor survival, while treatment options for relapsed or refractory (R\/R) disease remain quite limited, with a median progression-free survival of only 3\u20134 months. Notably, the emergence of innovative therapeutic agents and regimens holds promise for durable responses and improved survival for patients with R\/R PTCL. We summarize recent advances in the treatment of R\/R PTCL from the 2023 ASH Annual Meeting, highlighting novel agents targeting EZH1\/2, JAK1, PI3K, KIR3DL2, CD38\/CD3xCD28, or CDK9, as well as therapeutic regimens in combination with stem cell transplantation, immunomodulators, epigenetic modifying agents, or CD30\/CD16A bispecific antibodies.<\/jats:p>","DOI":"10.1186\/s40164-024-00510-w","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T13:01:39Z","timestamp":1713790899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting"],"prefix":"10.1186","volume":"13","author":[{"given":"Huageng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huangming","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"510_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40164-020-00188-w","volume":"9","author":"C Xie","year":"2020","unstructured":"Xie C, Li X, Zeng H, Qian W. Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma. Exp Hematol Oncol. 2020;9:30.","journal-title":"Exp Hematol Oncol"},{"key":"510_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-020-00889-z","volume":"13","author":"E Mulvey","year":"2020","unstructured":"Mulvey E, Ruan J. Biomarker-driven management strategies for peripheral T cell lymphoma. J Hematol Oncol. 2020;13:59.","journal-title":"J Hematol Oncol"},{"key":"510_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1182\/blood-2023-179304","volume":"142","author":"SM Horwitz","year":"2023","unstructured":"Horwitz SM, Izutsu K, Mehta-Shah N, Cordoba R, Barta SK, Bachy E, et al. Efficacy and Safety of Valemetostat Monotherapy in patients with relapsed or refractory peripheral T-Cell lymphomas: primary results of the phase 2 VALENTINE-PTCL01 study. Blood. 2023;142:302\u2013302.","journal-title":"Blood"},{"key":"510_CR4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1182\/blood-2023-180372","volume":"142","author":"H Hong","year":"2023","unstructured":"Hong H, Zhang M, Peng Z, Shen J, Shuang Y, Zhou H, et al. A multicenter, Open-Label, Single-Arm, phase ib clinical trial of HH2853 in the treatment of patients with relapsed and\/or refractory peripheral T-Cell lymphoma. Blood. 2023;142:304\u2013304.","journal-title":"Blood"},{"key":"510_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1182\/blood-2023-172962","volume":"142","author":"Y Song","year":"2023","unstructured":"Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, et al. Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: full analysis of the multinational pivotal study results (JACKPOT8). Blood. 2023;142:305\u2013305.","journal-title":"Blood"},{"key":"510_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1182\/blood-2023-180137","volume":"142","author":"Y Song","year":"2023","unstructured":"Song Y, Li Z, Wu H, Jin J, Zhou H, Zhou K, et al. A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T\/NK Cell Lymphomas. Blood. 2023;142:306\u2013306.","journal-title":"Blood"},{"key":"510_CR7","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1182\/blood-2023-173010","volume":"142","author":"B-S Kim","year":"2023","unstructured":"Kim B-S, Kim SJ, Yoon DH, Kim JS, Kim TM, Lee E, et al. A novel PI3K \u03b3\/\u03b4 and DNA-PK triple inhibitor, BR101801, for r\/r PTCL: a phase 1a\/b, Multi-center, open-label clinical trial. Blood. 2023;142:1701\u20131701.","journal-title":"Blood"},{"key":"510_CR8","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1182\/blood-2023-172537","volume":"142","author":"SP Iyer","year":"2023","unstructured":"Iyer SP, Ayyappan SR, Greenwell IB, Kim WS, Lee ST, Kim JS, et al. Strategies to develop Anti-KIR Mab Lacutamab in patients with peripheral T-Cell lymphoma: preliminary Monotherapy Clinical Data and Pre-clinical Combinability Data. Blood. 2023;142:3072\u20133072.","journal-title":"Blood"},{"key":"510_CR9","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1182\/blood-2023-189088","volume":"142","author":"A Dupuy","year":"2023","unstructured":"Dupuy A, Pelletier L, Giustiniani J, Kim P, Bisht K, Wang H, et al. The CD38\/CD3xCD28 trispecific antibody (SAR442257) potentially represents a Novel Therapeutic Strategy for Peripheral T-Cell Lymphomas. Blood. 2023;142:4384\u20134384.","journal-title":"Blood"},{"key":"510_CR10","doi-asserted-by":"publisher","first-page":"7133","DOI":"10.1182\/blood-2023-179419","volume":"142","author":"DS Potter","year":"2023","unstructured":"Potter DS, Ott I, Saeh J, Olsson R, Fawell S, Drew L, et al. AZD4573 in combination with CHOP increases Combination Benefit in Preclinical Peripheral T-Cell Lymphomas models. Blood. 2023;142:7133\u20137133.","journal-title":"Blood"},{"key":"510_CR11","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1182\/blood-2023-178231","volume":"142","author":"SS Tolu","year":"2023","unstructured":"Tolu SS, Gribbin C, Seshadri MR, Chen Z, Orlando E, Grenet J, et al. Outcomes of contemporary Novel Agent and Stem Cell Transplantation in Relapsed\/Refractory PTCL. Blood. 2023;142:1698\u20131698.","journal-title":"Blood"},{"key":"510_CR12","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2023-181809","volume":"142","author":"SJ Kim","year":"2023","unstructured":"Kim SJ, Lee M-W, Lim S-N, Kang K-W, Yoon SE, Lee YJ, et al. Phase II study of Lenalidomide Maintenance after salvage therapy for relapsed or refractory peripheral T-Cell lymphomas. Blood. 2023;142:3073\u20133073.","journal-title":"Blood"},{"key":"510_CR13","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1182\/blood-2023-188801","volume":"142","author":"J Yu","year":"2023","unstructured":"Yu J, Lu Y, Yao Y, Liu X, Li L, Qian Z, et al. Azacitidine for Injection Combined with Chidamide in Relapsed\/Refractory Peripheral T-Cell Lymphoma: a phase I study. Blood. 2023;142:3076\u20133076.","journal-title":"Blood"},{"key":"510_CR14","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1182\/blood-2023-185902","volume":"142","author":"Z Yan","year":"2023","unstructured":"Yan Z, Yao S, Zhao S, Wang H, Chu J, Xu Y, et al. Selective PI3K\u03b4 inhibitor parsaclisib combined with HDAC inhibitor chidamide in patients with Relapsed\/Refractory peripheral T-Cell lymphoma: preliminary results of a phase Ib\/II study. Blood. 2023;142:3075\u20133075.","journal-title":"Blood"},{"key":"510_CR15","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1182\/blood-2023-174250","volume":"142","author":"A Moskowitz","year":"2023","unstructured":"Moskowitz A, Harstrick A, Emig M, Overesch A, Pinto S, Ravenstijn P, et al. AFM13 in combination with allogeneic natural killer cells (AB-101) in relapsed or refractory Hodgkin Lymphoma and CD30\u2009+\u2009peripheral T-Cell lymphoma: a phase 2 study (LuminICE). Blood. 2023;142:4855\u20134855.","journal-title":"Blood"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-024-00510-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-024-00510-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-024-00510-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T13:05:59Z","timestamp":1713791159000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-024-00510-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["510"],"URL":"https:\/\/doi.org\/10.1186\/s40164-024-00510-w","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"assertion":[{"value":"8 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"44"}}